SCNI
NASDAQ
$0.25
Scinai Immunotherapeutics Ltd (SCNI)
Scinai Immunotherapeutics Ltd is an innovative biotechnology company focused on developing cutting-edge immunotherapy solutions for cancer and autoimmune disorders. Leveraging its proprietary immune modulation platform, Scinai is advancing a comprehensive clinical pipeline that aims to deliver transformative therapies to enhance patient outcomes. With a seasoned leadership team and a strong commitment to rigorous research, the company is poised to capitalize on the increasing demand for advanced immunotherapeutics in the global healthcare sector. Strategic partnerships further augment Scinai's growth potential, positioning it as a significant contender within the biopharmaceutical industry.
Sector:
Healthcare
Industry:
Biotechnology
Target: $700 (+285497.72%)
Market Cap
$912K
P/B Ratio
0.20
Beta (5Y)
0.82
Price Chart
Valuation
Market Cap$912K
P/S0.97
P/B0.20
Profitability
Total Revenue (TTM)$1.31M
Gross Profit (TTM)-$4M
EBITDA-$6.12M
Profit Margin-261.4%
Operating Margin-504%
EPS-$2.40
Growth & Risk
Beta (5Y)0.82
Sharpe Ratio-1.34